VTGN

2.10

0.47% -0.010

Handel nachbörslich: 2.15 0.05 +2.38%

Vistagen Therapeutics Inc (VTGN)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$2.11

Offen:

$2.1

24-Stunden-Volumen:

103.27K

Relative Volume:

0.70

Marktkapitalisierung:

$64.36M

Einnahmen:

$875.70K

Nettoeinkommen (Verlust:

$-39.57M

KGV:

-1.5645

EPS:

-1.3423

Netto-Cashflow:

$-33.65M

1W Leistung:

-5.83%

1M Leistung:

-24.73%

6M Leistung:

-30.00%

1J Leistung:

-55.88%

1-Tages-Spanne:

$2.01

$2.14

1-Wochen-Bereich:

$1.965

$2.32

52-Wochen-Spanne:

$1.90

$5.00

Vistagen Therapeutics Inc Stock (VTGN) Company Profile

Firmenname

Vistagen Therapeutics Inc

Sektor

Healthcare (1155)

Branche

Biotechnology (677)

Telefon

650-577-3600

Adresse

343 ALLERTON AVENUE, SOUTH SAN FRANCISCO

Mitarbeiter

Twitter

@vistagen

Nächster Verdiensttermin

2024-11-07

Neueste SEC-Einreichungen

VTGN's Discussions on Twitter

Vergleichen Sie VTGN mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
VTGN Vistagen Therapeutics Inc	2.10	64.36M	875.70K	-39.57M	-33.65M	-1.3423
VRTX Vertex Pharmaceuticals Inc	477.52	127.47B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	561.49	62.43B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	595.70	37.03B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	232.75	31.06B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	229.22	26.16B	3.81B	-644.79M	-669.77M	-6.24

Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2023-12-07	Hochstufung	Jefferies	Hold → Buy
2023-08-07	Hochstufung	Maxim Group	Hold → Buy
2022-07-22	Herabstufung	Jefferies	Buy → Hold
2022-07-22	Herabstufung	Robert W. Baird	Outperform → Neutral
2022-07-22	Herabstufung	William Blair	Outperform → Mkt Perform
2021-05-20	Eingeleitet	Robert W. Baird	Outperform
2021-02-18	Eingeleitet	Jefferies	Buy
2021-01-04	Hochstufung	William Blair	Mkt Perform → Outperform
2018-06-27	Eingeleitet	Maxim Group	Buy
2018-02-08	Bestätigt	Chardan Capital Markets	Buy
2017-03-28	Eingeleitet	Maxim Group	Buy

Alle ansehen

Vistagen Therapeutics Inc Aktie (VTGN) Neueste Nachrichten

Apr 17, 2025

Social Anxiety Crisis: 48% of Young Adults Report Suicidal Thoughts, Treatment Gap Widens - Stock Titan

Apr 17, 2025

Apr 08, 2025

Financial Survey: Vistagen Therapeutics (NASDAQ:VTGN) versus IO Biotech (NASDAQ:IOBT) - Defense World

Apr 08, 2025

Apr 06, 2025

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Shares Purchased by Blair William & Co. IL - Defense World

Apr 06, 2025

Apr 04, 2025

VTGN Stock Touches 52-Week Low at $2.21 Amid Market Challenges - Investing.com UK

Apr 04, 2025

Apr 03, 2025

VistaGen Therapeutics to Present at the Cowen and Company 39th Annual Health Care Conference on March 13, 2019 - ACCESS Newswire

Apr 03, 2025

Mental Disorder Treatment Market Set to Witness Significant - openPR.com

Apr 03, 2025

Mar 24, 2025

Vistagen Therapeutics (NASDAQ:VTGN) Shares Cross Above Fifty Day Moving AverageHere's Why - MarketBeat

Mar 24, 2025

Mar 21, 2025

Generalized Anxiety Disorder Treatment Market Size in 7MM - openPR.com

Mar 21, 2025

Vistagen Therapeutics (NASDAQ:VTGN) Share Price Passes Above 50-Day Moving Average – Should You Sell? - Defense World

Mar 21, 2025

Mar 19, 2025

Vistagen to Present at the 2025 Anxiety and Depression Association Conference - Sharewise

Mar 19, 2025

Groundbreaking Social Anxiety Treatment Research: Vistagen Reveals New Clinical Data at ADAA 2025 - StockTitan

Mar 19, 2025

Mar 14, 2025

Vistagen Therapeutics (NASDAQ:VTGN) Shares Cross Below 50 Day Moving AverageTime to Sell? - MarketBeat

Mar 14, 2025

Mar 12, 2025